Clinical trials: BRONCHIAL ASTHMA
Asthma
Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma
This is a multicentre, randomized, single-blind, active-controlled, parallel-group phase III local registration study for a treatment period of 12 weeks.
- Trial name
- NCT01687283
- Testing
- fluticasone propionate inhalation solution, budesonide suspension
- Where
- 25 sites in China
- Volunteers
- 316 people
- Sponsor
- GlaxoSmithKline
Exercise-Induced Asthma
Study of Oglemilast for the Prevention of Asthma.
The purpose of this study is to determine whether it is effective in the treatment of exercise-induced asthma and investigate the safety of oglemilast.
- Trial name
- NCT00322283
- Testing
- Oglemilast
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Forest Laboratories
Patient Satisfaction
Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment
The main aim of the study is to investigate patient satisfaction in the treatment of asthma and COPD with the new device of DuoResp® Spiromax® and patient preference.
- Trial name
- NCT02384577
- Testing
- Budesonide, Formoterol Fumarate Dihydrate
- Where
- Germany
- Volunteers
- 4,034 people
- Sponsor
- Teva Pharma GmbH
Allergic Asthma
Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)
In this study patients suffering from Immunoglobulin E (IgE) mediated asthma are treated with a method, called immune apheresis, that removes IgE from blood.
- Trial name
- ESPIRA (NCT02096237)
- Testing
- IgE adsorber
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Asthma
A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)
This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety and tolerability of MEMP1972A when administered to patients by intravenous (IV) infusion for the…
- Trial name
- NCT01196039
- Testing
- MEMP1972A
- Where
- 7 sites in Canada, Sweden
- Volunteers
- 29 people
- Sponsor
- Genentech, Inc.
Asthma
Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma
The purpose of this study is to determine the efficacy of indacaterol 55µg once daily (and 27.5 µg twice) in QVA149 compared to 75 µg indacaterol monotherapy.
- Trial name
- QAB149 (NCT01959412)
- Testing
- Indacaterol 27.5 mcg, Indacaterol 37.5, Indacaterol 55 mcg
- Where
- 12 sites in United States
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study (0476-176)
A study of Montelukast compared to placebo in asthmatic children aged 6-24 months.
- Trial name
- NCT00943683
- Testing
- montelukast sodium
- Volunteers
- 256 people
- Sponsor
- Organon and Co
Severe Asthma
Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes
Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β2-agonists.
- Trial name
- Betreat (NCT07159295)
- Where
- 16 sites in Portugal
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Uncontrolled Asthma
Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy
The purpose of this study is to evaluate the efficacy and safety of CHF6001 (Tanimilast) as add-on to maintenance of inhaled corticosteroids in combination with Long-acting ß2-agonists in the target patient population. (TANGO)
- Trial name
- TANGO (NCT06029595)
- Testing
- Experimental: CHF6001 3200 μg
- Where
- 187 sites in Argentina, Bulgaria and 12 more
- Volunteers
- 517 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)
Primary objective The primary objective was to evaluate the superiority of CHF 5259 (glycopyrronium bromide [GB]) in a pressurised metered dose inhaler (pMDI) (50 μg total daily dose) versus placebo in terms of forced expiratory…
- Trial name
- ELITRA (NCT02296411)
- Testing
- CHF 5259 12.5 µg + Qvar
- Where
- 28 sites in Bulgaria, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Asthma
Budesonide/Formoterol for Maintenance and Reliever Therapy Among Asthma Patients in Thailand
The purpose of this study is to determine the incidence of misuse, i.e., over-use and under-use, of Budesonide/formoterol for maintenance and reliever therapy in usual-care setting.
- Trial name
- NCT00800241
- Where
- 14 sites in Thailand
- Volunteers
- 1,020 people
- Sponsor
- AstraZeneca
Asthma
Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics
This study will evaluate the correct use of sequential formoterol and budesonide inhaler capsule treatment via Aerolizer and patient satisfaction in adult asthmatics.
- Trial name
- NCT00997477
- Testing
- Foradil Combi (Formoterol-budesonide)
- Where
- 4 sites in Turkey (Türkiye)
- Sponsor
- Novartis Pharmaceuticals
Asthma With Eosinophilic Phenotype
A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype.
- Trial name
- NCT05522439
- Testing
- SHR-1703
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Asthma, Chronic Obstructive Pulmonary Disease
Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease
The study is to evaluate the percentage of patients with asthma or COPD achieving disease control
- Trial name
- SPRINT (NCT02419872)
- Testing
- Marketed antagonists
- Where
- 141 sites in Croatia, Denmark and 8 more
- Volunteers
- 1,743 people
- Sponsor
- Teva Pharmaceuticals Europe
Asthma
Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms
Overall Aim: To better understand the diagnostic process for prolonged respiratory events and determine the potential role of FeNO in assessing the possibility of asthma as the symptoms etiology.
- Trial name
- NCT01518322
- Testing
- NIOX MINO®
- Where
- 13 sites in United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Aerocrine AB
Healthy Participants, Asthma
A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics
This is a single-center, randomized, double-blind, placebo-controlled, phase 1, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3002 in healthy participants…
- Trial name
- NCT06213844
- Testing
- IBI3002
- Where
- Australia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Asthma
Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma
This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma
- Trial name
- NCT01103037
- Testing
- QAV680
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with…
- Trial name
- FAROS (NCT07525375)
- Testing
- GP MDI, BFF MDI
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Severe Eosinophilic Asthma, Nasal Polyps
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
- Trial name
- RANS (NCT05180357)
- Testing
- FASENRA(benralizumab)
- Where
- 45 sites in United States, France and 4 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.